http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-69530511-T2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-873 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-822 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-849 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P17-182 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P17-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-37 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P17-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 |
| filingDate | 1995-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5453d42f55d91ce59b86bd92994fe71b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9e16271118fc19add216ff828d9a0da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e8066a25d92b826901a9ac9cf2b68d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05248d541fc4b9617591541cf0c14dfe |
| publicationDate | 2004-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-69530511-T2 |
| titleOfInvention | ENANTIOSELECTIVE PRODUCTION OF PHARMACEUTICALLY ACTIVE SULFOXIDES BY BIOREDUCTION |
| abstract | PCT No. PCT/SE95/01416 Sec. 371 Date Dec. 18, 1995 Sec. 102(e) Date Dec. 18, 1995 PCT Filed Nov. 27, 1995A compound of formula (II), either as a single enantiomer or in an enantiomerically enriched form <IMAGE> (II) wherein: <IMAGE> and <IMAGE> <IMAGE> (wherein N in the benzimidazole moiety of Het2 means that one of the carbon atoms substituted by any one of R6 to R9 optionally may be exchanged for an unsubstituted nitrogen atom; R1, R2 and R3 are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl, phenylakoxy; R4 and R4, are the same or different and selected from hydrogen, alkyl, aralkyl; R5 is hydrogen, halogen, trifluoromethyl, alkyl, alkoxy; R6 -R9 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl or adjacent groups R6 -R9 may complete together with the carbon atoms to which they are attached optionally substituted ring structures; R10 is hydrogen or alkoxycarbonyloxymethyl; R11 is hydrogen or forms an alkylene chain together with R3; R12 and R13 are the same or different and selected from hydrogen, halogen or alkyl) is obtained by stereoselective bioreduction of a compound of formula (II) in racemic form. |
| priorityDate | 1994-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467857152 |
Total number of triples: 29.